Project Number 5P50AG025688-10 Agency/Funding Organization NIA Funding Year 2014 View Full Project Details for NOREPINEPHRINE-TrkB INTERATIONS IN Alzheimer's DISEASE Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category C. Translational Research and Clinical Interventions 3. Drug Discovery (small molecules and biologics) m. Synaptic Plasticity/Neuroprotection Category F. Research Resources 1. Alzheimer's Disease Centers Researcher and Organization Principal Investigator WEINSHENKER, DAVID Principal Investigator First Name DAVID Principal Investigator Last Name WEINSHENKER Awardee Organization EMORY UNIVERSITY Awardee State Georgia Contact PI Country United States Project Detail Funding Opportunity Announcement RFA-AG-10-002: ALZHEIMER'S DISEASE RESEARCH CENTERS (P50) FY Overall Cost $190,801 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official PHELPS, CREIGHTON H. Related Resources Repository [NIAGADS] ADC3- Alzheimer Disease Center Dataset 3 [NIAGADS] ADGC African American Summary Statistics- Reitz et al. (2013) [NIAGADS] ADGC Neuropath Summary Stats and Phenotypes- Beecham et al. (2014) [NIAGADS] ADGC Summary Statistics- Naj et al. (2011) [NIAGADS] ADC1- Alzheimer Disease Center Dataset 1 [NIAGADS] ADC2- Alzheimer Disease Center Dataset 2 Emory University Alzheimer's Disease Research Center National Alzheimer's Coordinating Center (NACC) [AlzPED] Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice [AlzPED] 7,8-dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer's disease
